Testing

In May 2019, Mayo Clinic Laboratories announced four new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By Emily Linginfelter • June 5, 2019

The standard test for the diagnosis of narcolepsy is the multiple sleep latency test (MSLT). The MSLT is a complex test to perform as well as to interpret. The orexin-A/hypocretin-1 test is a sensitive and specific alternative to the MSLT to diagnose type 1 narcolepsy.

By Alyssa Frank • May 31, 2019

The presence NTRK gene fusions is one of the eligibility requirements for the recently FDA-approved therapy Vitrakvi (larotrectinib), a therapy indicated in adult and pediatric patients with solid tumors regardless of the type of tumor. NTRK gene fusions have been described in many cancers at various frequencies including common cancers such as lung, thyroid, and colorectal cancers.

By Alyssa Frank • May 22, 2019

As the world leader in the diagnosis and treatment of gastrointestinal conditions for the last 28 years, we know the importance of laboratory testing in a patient’s care. Visit us at Digestive Disease Week 2019, May 19—21, Booth #2927.

By mayocliniclabs • May 17, 2019

Joseph Yao, M.D., gives an overview of this new test available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing improves upon other testing approaches, and what clinical action can be taken due to the results of this testing.

By Alyssa Frank • May 8, 2019

Neuro-oncology is a complex field undergoing rapid changes with the advancement and evolution of sophisticated genetic testing. Evidence continues to grow in support of broad molecular and cytogenetic analysis for patients with brain tumors.

By Alyssa Frank • May 7, 2019

View a full list of new CPT codes, Test Classification Updates, LOINC Codes, and Z-Codes posted to mayocliniclabs.com during the month of April 2019.

By Andy Tofilon • May 6, 2019

The diagnosis of mitochondrial disease can be particularly challenging as the presentation can occur at any age, involve virtually any organ system, and be associated with widely varying severities. Due to the considerable overlap in the clinical phenotypes of various mitochondrial disorders, it is often difficult to distinguish these specific inherited disorders without genetic testing.

By Alyssa Frank • May 3, 2019

In April 2019, Mayo Clinic Laboratories announced nine new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By Emily Linginfelter • May 2, 2019

As the world leader in the diagnosis and treatment of neurologic conditions, we know the importance of laboratory testing in a patient’s episode of care. Visit us at booth #1301 at AAN 2019 to discuss how our testing can integrate with your practice.

By mayocliniclabs • May 1, 2019

The current diagnostic tools in a pathologist’s arsenal sometimes cannot provide a clear distinction between primary mediastinal large B-cell lymphoma (one of the few lymphomas more common in younger women) and diffuse large B-cell lymphoma, the most common type of non-Hodgkin’s lymphoma overall.

By Suzanne R. Ferguson • April 30, 2019

The standard laboratory test to diagnose multiple myeloma dates back to the Eisenhower administration. Research at Mayo Clinic spearheaded by David Murray, M.D., Ph.D. (PATH ’10), and fueled by his experience as an industrial chemist has led to a new assay to screen and diagnose the disease.

By mayocliniclabs • April 29, 2019

Joshua Bornhorst, Ph.D., gives an overview of the new Copeptin test available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.

By Alyssa Frank • April 18, 2019